Deals channel feed – Endpoints News

Deals channel feed

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

6 years ago

Sanofi aligns itself with Google to streamline drug development

6 years ago

Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

6 years ago

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

6 years ago

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

6 years ago

Pfizer CEO Albert Bourla is back in the M&A game, but why is he paying $11.4B for Array?

6 years ago

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

6 years ago

GSK's Barron joins hands with Doudna, Weissman to deploy CRISPR tech in drug discovery

6 years ago

Merck makes a $773M bet on TGFβ, acquiring a three-year-old biotech

6 years ago

Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout

6 years ago

R&D leader Vertex executes a $420M cash gambit to dominate gene editing field for Duchenne MD

6 years ago

Vical finds way out of R&D woes via reverse merger with dermatology biotech Brickell

6 years ago

Amgen offers to swallow Denmark-based drug discovery partner in $167M deal

7 years ago

Beleaguered Biogen faces the music as a rising chorus of critics push for a transformative approach to M&A

7 years ago

Germany's Evotec expands into biologics with up to $90M deal for Seattle's Just Biotherapeutics

7 years ago

Merck bets $2.2B on a small cancer drug biotech, snatching it out of the IPO lineup

7 years ago

What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay

7 years ago

Hit by setbacks, Lundbeck's Deborah Dunsire inks a $400M cannabinoid buyout, adding a discovery site

7 years ago

Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock

7 years ago

Canine club: Elanco Animal Health makes takeover play for partner Aratana in up to $245M deal

7 years ago

Roche delays $4.3B Spark buyout — again — as FTC review drags on

7 years ago

Whale watching: What a decade of change at Big Pharma taught us about corporate phenotypes

7 years ago

T cell experts at Kiadis bag CytoSen's NK cell tech, plotting a dual cancer killing approach with tips from Carl June

7 years ago

Ahead of US gene therapy explosion, big contract drug manufacturer Catalent makes $1.2 billion bet on Paragon Bioservices

7 years ago

First page Previous page 103 104 105106107 108 109 Next page Last page